Patients had fewer MACE over 4 years compared with a standard systolic target, but some had worsened renal function.

The drug failed to reduce CV events in the RCT, but it’s clear many still hold out hope for the inflammatory hypothesis.

One trial does not disprove the concept that lowering Lp(a) can reduce CV risk, Steven Nissen stresses, with “more work to do ...

A “successful” procedure may have a different meaning to the heart team than to the patient, Misty Theriot stressed.

SAN DIEGO, CA—The novel ProtEmbo device (Protembis) for cerebral embolic protection (CEP) during TAVI is safe to use but does ...

Using previously obtained CT scans, operators were able to plan procedures ahead of time, with no ill effects on outcome.

At 6 months, the win ratio favored the device over optimal medical therapy, in large part driven by improved quality of life.

The IRIS-MAIN registry results did show some differences in nonfatal outcomes like stroke, MI, and revascularization.

SAN DIEGO, CA—Patients treated with the Agent drug-coated balloon (DCB; Boston Scientific) have encouraging outcomes at 1 ...

Underdiagnosis and undertreatment likely drive the profound effects observed in certain populations, says Juan Granada.

REMEDY-PILOT showed the safety and feasibility of using the device, but with no effects on perfusion or angina symptoms.

The homogeneous formatting and look is leading many to question the integrity of those relying too heavily on these tools.